- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06771219
Um estudo de escalonamento de dose de fase 1 de SLV 154 em indivíduos com tumores sólidos metastáticos
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.
SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Langdon L Miller, MD
- Número de telefone: 908-906-6471
- E-mail: lmiller@solvetx.com
Estude backup de contato
- Nome: Hong Ren, MD
- Número de telefone: 425-894-2558
- E-mail: hren@solvetx.com
Locais de estudo
-
-
California
-
Newport Beach, California, Estados Unidos, 92663
- Recrutamento
- Hoag Memorial Hospital Presbyterian
-
Contato:
- Cindy Do, BSN, RN
- Número de telefone: 949-764-4624
- E-mail: cindy.do@hoag.org
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University
-
Contato:
- Sara Mitchum
- Número de telefone: 314-273-8602
- E-mail: saram@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Recrutamento
- Astera Cancer Care
-
Contato:
- Percy Yeung
- Número de telefone: 732-387-3378
- E-mail: percy.yeung@asterahealthcare.org
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Roisin O'Cearbhaill, MD
- Número de telefone: 646-888-4227
- E-mail: ocearbhr@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Recrutamento
- University Hospitals Cleveland Medical Center
-
Contato:
- Afshin Dowlati, MD
- Número de telefone: 212-844-6031
- E-mail: afshin.dowlati@UHhospitals.org
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- The James Outpatient Care West Center
-
Contato:
- Adam Roan
- Número de telefone: 614-685-0587
- E-mail: Adam.Roan@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Recrutamento
- Fox Chase Cancer Center
-
Contato:
- Dajah White-Dumpson
- Número de telefone: 215-214-1600
- E-mail: Dajah.White-Dumpson@fccc.edu
-
Contato:
- Shannon Fabrie
- Número de telefone: 215-728-3620
- E-mail: shannon.fabrie@fccc.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- MD Anderson Cancer Center
-
Contato:
- Rabia Khan
- Número de telefone: 713-563-4667
- E-mail: RKhan@mdanderson.org
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Oncology Consultants
-
Contato:
- Julio Peguero, MD
- Número de telefone: 713-600-0900
- E-mail: jPeguero@oncologyconsultants.com
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Mays Cancer Center; University of Texas Health San Antonio
-
Investigador principal:
- Daruka Mahadevan
-
Contato:
- Daruka Mahadevan, MD
- Número de telefone: 210-450-1000
- E-mail: mahadevand@uthscsa.edu
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- University of Washington / Fred Hutchinson Cancer Center
-
Contato:
- Phase 1 Clinical Trials
- Número de telefone: 206-606-7551
- E-mail: phase1clinicaltrial@fredhutch.org
-
Tacoma, Washington, Estados Unidos, 98405
- Recrutamento
- Northwest Medical Specialties, PLLC
-
Contato:
- CarrieAnn Brown
- Número de telefone: 253-428-8700
- E-mail: cbrown@nwmsonline.com
-
Contato:
- Kiersten Peart
- Número de telefone: 253-428-8700
- E-mail: kpeart@nwmsonline.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men or women (as appropriate for cancer type) of age ≥12 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
- Presence of metastatic or recurrent locally advanced cancer.
- Presence of radiographically measurable disease.
- Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
- Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- Adequate hematological profile.
- Adequate coagulation profile.
- Adequate hepatic profile.
- Adequate renal function.
- Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- For female subjects of childbearing potential, a negative serum pregnancy test.
- For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Unstable malignancy involving the central nervous system.
- Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- Significant cardiovascular event or comorbidity.
- Significant screening ECG abnormalities.
- Pregnancy or breastfeeding.
- Major surgery within 3 weeks before the start of study therapy.
- Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
- Concurrent participation in another therapeutic or imaging clinical trial.
- Other conditions likely to interfere with a subject's ability to participate in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dose Level 1
0.75 mg/kg |
SLV-154 |
|
Experimental: Dose Level 2
1.5 mg/kg |
SLV-154 |
|
Experimental: Dose Level 3
3.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 4
4.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 5
5.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 6
6.5 mg/kg |
SLV-154 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1a: MTD and/or RDR
Prazo: Through the duration of treatment, up to approximately 18 months
|
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154. |
Through the duration of treatment, up to approximately 18 months
|
|
Phase 1b: Objective response rate (ORR)
Prazo: Through the duration of treatment, up to approximately 18 months
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Through the duration of treatment, up to approximately 18 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
SLV-154 administration
Prazo: Through the duration of treatment, up to approximately 18 months
|
SLV-154 drug administration as assessed by prescribing records |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Safety
Prazo: Through the duration of treatment, up to approximately 18 months
|
Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration. |
Through the duration of treatment, up to approximately 18 months
|
|
Evaluation of use of concomitant medications
Prazo: Through the duration of treatment, up to approximately 18 months
|
Type, frequency, and timing of use of supportive care and other concomitant medications |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Pharmacokinetics
Prazo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Evaluation of the pharmacokinetic profile of SLV-154 |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Immunogenicity
Prazo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods) |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Time to Response (TTR)
Prazo: Up to approximately 36 months
|
TTR: interval from the start of study drug administration to the first documentation of objective tumor regression |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Prazo: Up to approximately 36 months
|
DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
4-month progression-free survival (PFS4)
Prazo: Up to approximately 36 months
|
PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration |
Up to approximately 36 months
|
|
6-month progression-free survival (PFS6)
Prazo: Up to approximately 36 months
|
PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration |
Up to approximately 36 months
|
|
Time to treatment failure (TTF)
Prazo: Up to approximately 36 months
|
TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause |
Up to approximately 36 months
|
|
Overall survival (OS)
Prazo: Up to approximately 36 months
|
OS: interval from the start of study drug administration to death from any cause |
Up to approximately 36 months
|
|
Disease benefit ratio (DBR)
Prazo: Up to approximately 36 months
|
DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR) |
Up to approximately 36 months
|
|
Progression free survival (PFS)
Prazo: Up to approximately 36 months
|
PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
Duration of disease benefit (DDB)
Prazo: Up to approximately 36 months
|
DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit |
Up to approximately 36 months
|
|
Percent change in tumor dimensions
Prazo: Up to approximately 36 months
|
percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions |
Up to approximately 36 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SLV-154-01Tx
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .